Litcius/Paper detail

Contemporary Approach to Neurofibromatosis Type 1–Associated Malignant Peripheral Nerve Sheath Tumors

Angela C. Hirbe, Carina Dehner, Eva Dombi, Vanessa Eulo, Andrea M. Gross, R. Taylor Sundby, Alexander J. Lazar, Brigitte C. Widemann

2024American Society of Clinical Oncology Educational Book26 citationsDOIOpen Access PDF

Abstract

Most malignant peripheral nerve sheath tumors (MPNSTs) are clinically aggressive high-grade sarcomas, arising in individuals with neurofibromatosis type 1 (NF1) at a significantly elevated estimated lifetime frequency of 8%-13%. In the setting of NF1, MPNSTs arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. Composed of neoplastic cells from the Schwannian lineage, these cancers recur in approximately 50% of individuals, and most patients die within five years of diagnosis, despite surgical resection, radiation, and chemotherapy. Treatment for metastatic disease is limited to cytotoxic chemotherapy and investigational clinical trials. In this article, we review the pathophysiology of this aggressive cancer and current approaches to surveillance and treatment.

Topics & Concepts

NeurofibromatosisMedicineMalignant peripheral nerve sheath tumorNeurofibromaRadiation therapyMalignant transformationPathologyPlexiform neurofibromaChemotherapyNeurofibromatosis type IOncologyRadiologyInternal medicineNeurofibromatosis and Schwannoma CasesSoft tissue tumors and treatmentSarcoma Diagnosis and Treatment